Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05), Zacks reports.
Oric Pharmaceuticals Price Performance
ORIC stock traded down $0.34 on Monday, reaching $7.52. 1,196,157 shares of the company traded hands, compared to its average volume of 1,714,194. Oric Pharmaceuticals has a one year low of $7.23 and a one year high of $14.68. The company has a market cap of $779.47 million, a P/E ratio of -5.57 and a beta of 1.23. The firm has a fifty day simple moving average of $11.56 and a 200-day simple moving average of $11.01.
Insider Activity
In other news, CFO Dominic Piscitelli sold 77,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total value of $1,054,130.00. Following the transaction, the chief financial officer owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several brokerages have commented on ORIC. Stifel Nicolaus raised their price objective on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, October 26th. Wedbush decreased their target price on Oric Pharmaceuticals from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, October 27th. JPMorgan Chase & Co. raised their target price on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, October 15th. Finally, Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $21.25.
Read Our Latest Research Report on ORIC
About Oric Pharmaceuticals
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Further Reading
- Five stocks we like better than Oric Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
